Enable Biotech is a Swiss-based Contract Development and Manufacturing Organisation (CDMO), founded in 2023, focusing on the production of advanced therapies, including cell and gene therapies, and exosome therapies. The company provides tailored, phase-adapted services to clinical-stage companies, offering efficient, flexible, and cost-effective solutions for early-stage clinical development.

Key Products and Services

• Clinical GMP manufacturing of cell therapies and exosome therapies
• Gene therapy manufacturing (SwissMedic accreditation pending)
• Process development for cell and gene therapies
• Gene editing using viral vectors (AAV, LVV) and electroporation
• CMC services for regulatory submissions

Enable Biotech’s innovative approach and highly experienced team provide vital support for start-ups and spin-offs in the advanced therapy field, ensuring the smooth transition of their products into clinical trials.